The recent halt of a study involving Eli Lilly's experimental Alzheimer's disease drug, a compound known as a gamma secretase inhibitor, has some experts speculating on what could have went wrong with the drug. The drug was designed to target the brain's amyloid protein, which is thought to accelerate the development of the disease. One angle being considered is that amyloid is really an effect of the disease, not its cause, and targeting it could make the disease worse.

Full Story:

Related Summaries